Subject(s)
Exome , Genome, Human , Incidental Findings , Humans , Exome/genetics , Exome Sequencing/methods , Genomics/methods , Genomics/trendsSubject(s)
Genetic Testing , Genomics , High-Throughput Nucleotide Sequencing , Sequence Analysis, DNA , Genomics/methods , Genomics/trends , High-Throughput Nucleotide Sequencing/methods , High-Throughput Nucleotide Sequencing/trends , Sequence Analysis, DNA/methods , Sequence Analysis, DNA/trends , Genetic Testing/methods , Genetic Testing/trends , HumansABSTRACT
Africa bears a disproportionate burden of infectious diseases, accounting for a substantial percentage of global cases. Malaria, HIV/AIDS, tuberculosis, cholera, Ebola, Lassa fever, and other tropical diseases, such as dengue and chikungunya, have had a profound impact on morbidity and mortality. Various factors contribute to the higher prevalence and incidence of infectious diseases in Africa, including socioeconomic challenges, limited access to health care, inadequate sanitation and hygiene infrastructure, climate-related factors, and endemicity of certain diseases in specific regions. A skilled workforce is crucial to addressing these challenges. Unfortunately, many countries in Africa often lack the required resources, and aspiring scientists frequently seek educational and career opportunities abroad, leading to a substantial loss of talent and expertise from the continent. This talent migration, referred to as "brain drain," exacerbates the existing training gaps and hampers the sustainability of research within Africa.
Subject(s)
Communicable Diseases , Genomics , Global Burden of Disease , Humans , Africa/epidemiology , Workforce , Communicable Diseases/economics , Communicable Diseases/epidemiology , Communicable Diseases/mortality , Prevalence , Incidence , Brain Drain , Genomics/economics , Genomics/trendsABSTRACT
Many of the Earth's microbes remain uncultured and understudied, limiting our understanding of the functional and evolutionary aspects of their genetic material, which remain largely overlooked in most metagenomic studies1. Here we analysed 149,842 environmental genomes from multiple habitats2-6 and compiled a curated catalogue of 404,085 functionally and evolutionarily significant novel (FESNov) gene families exclusive to uncultivated prokaryotic taxa. All FESNov families span multiple species, exhibit strong signals of purifying selection and qualify as new orthologous groups, thus nearly tripling the number of bacterial and archaeal gene families described to date. The FESNov catalogue is enriched in clade-specific traits, including 1,034 novel families that can distinguish entire uncultivated phyla, classes and orders, probably representing synapomorphies that facilitated their evolutionary divergence. Using genomic context analysis and structural alignments we predicted functional associations for 32.4% of FESNov families, including 4,349 high-confidence associations with important biological processes. These predictions provide a valuable hypothesis-driven framework that we used for experimental validatation of a new gene family involved in cell motility and a novel set of antimicrobial peptides. We also demonstrate that the relative abundance profiles of novel families can discriminate between environments and clinical conditions, leading to the discovery of potentially new biomarkers associated with colorectal cancer. We expect this work to enhance future metagenomics studies and expand our knowledge of the genetic repertory of uncultivated organisms.
Subject(s)
Archaea , Bacteria , Ecosystem , Evolution, Molecular , Genes, Archaeal , Genes, Bacterial , Genomics , Knowledge , Antimicrobial Peptides/genetics , Archaea/classification , Archaea/genetics , Bacteria/classification , Bacteria/genetics , Biomarkers , Cell Movement/genetics , Colorectal Neoplasms/genetics , Genomics/methods , Genomics/trends , Metagenomics/trends , Multigene Family , Phylogeny , Reproducibility of ResultsABSTRACT
ABSTRACT Objective: A scientometric analysis produced in ophthalmic genetics and gene therapy research is lacking. The purpose of this study is to present a holistic analysis of ophthalmic genetics literature. Methods: The data used in this study were obtained from the Web of Science (WoS) Core Collection. All published documents between 1975-2019 were included. The data exported from WoS enabled the extensive details of ophthalmic genetics related literature including countries, institutions, authors, citations and keywords. Scientometric network maps of keywords and also country and institution co-authorships were created with free software. Global contributions of the countries to the ophthalmic genetics literature were shown by a graphic. Results: The search query revealed a total of 2322 documents. Most of the documents were original articles (75.75%). USA was the leading country by producing 45.39% of all documents in ophthalmic genetics research followed by UK, Germany, China and France. Pennsylvania University was the most contributing institution in the literature (5.25%) followed by University College London and Moorfields Eye Hospital. The average citations per item was 29.4. The most used keywords over a 40-year period were 'family', 'cell', 'photoreceptor' and 'expression'. Conclusions: USA and UK dominated the ophthalmic genetics research. A substantial increase in the number of published documents in this field were observed after 2010.
RESUMO Objetivo: A literatura carece de análise cienciométrica produzida em genética oftálmica e de pesquisa em terapia genética. O objetivo deste estudo é apresentar uma análise holística da literatura genética oftálmica. Métodos: Os dados utilizados neste estudo foram obtidos na base de dados Web of Science (WoS) Core Collection. Todos os documentos publicados entre 1975 e 2019 foram incluídos na análise. Os dados exportados da WoS viabilizaram acesso a amplos detalhes da literatura relacionada à genética oftálmica, incluindo países, instituições, autores, citações e palavras-chave. Mapas de rede cienciométrica foram criados por meio de software gratuito, com base em palavras-chave e em coautorias de países e instituições. As contribuições globais dos países para a literatura sobre genética oftálmica foram apresentadas em gráfico. Resultados: a busca por pesquisas revelou um total de 2.322 documentos cuja maioria eram artigos originais (75,75%). Os EUA foram o país que mais produziu artigos sobre o tema, com 45,39% de todos os documentos em pesquisa genética oftálmica; ele foi seguido pelo Reino Unido, Alemanha, China e França. A Universidade da Pensilvânia foi a instituição que mais contribuiu para a literatura (5,25%), e foi seguida pela University College London e pelo Moorfields Eye Hospital. A média de citações por item foi de 29,4. As palavras-chave mais usadas em um período de 40 anos foram 'família', 'célula', 'fotorreceptor' e 'expressão'. Conclusões: Os EUA e o Reino Unido dominaram a pesquisa em genética oftálmica. Após 2010, observou-se um aumento substancial no número de documentos publicados nessa área.
Subject(s)
Humans , Genetic Therapy , Bibliometrics , Eye Diseases, Hereditary , Eye Diseases/genetics , Eye Diseases/therapy , Ophthalmology/trends , Periodicals as Topic/trends , Periodicals as Topic/statistics & numerical data , Publications , Publishing/statistics & numerical data , Databases, Factual , Genomics/trends , Genetic ResearchABSTRACT
En los antecedentes se presentan estadísticas del COVID-19 a la fecha en la que se elaboró el documento (enero 2021) y aborda las tres mutaciones del virus conocidas hasta la fecha del documento. "La caracterización genética de patógenos virales es la base para el desarrollo de protocolos de diagnóstico, vacunas y medicamentos antivirales. Esta estrategia también es una herramienta útil en salud pública para el seguimiento a brotes y control de enfermedades mediante estudios de epidemiología molecular." " la secuenciación genómica del SARS-CoV-2 y la liberación oportuna de la información no solo permitió la caracterización del agente etiológico involucrado en el brote inicial, sino también el desarrollo oportuno de protocolos de diagnóstico y seguimiento a la evolución de la pandemia de COVID-19. Así, la secuenciación genómica se ha convertido en una herramienta esencial para generar datos virológicos de SARS-CoV-2, para impulsar la respuesta de laboratorio, y entender mejor los patrones de dispersión y evolución de SARS-CoV-2" De manera que el objetivo del documento es: "Generar información genética mediante la vigilancia genómica de casos confirmados de COVID-19 de pacientes que asisten a los servicios de salud públicos y privados del país, así como del Instituto Guatemalteco de Seguridad Social IGSS-."
Subject(s)
Humans , Male , Female , Coronavirus Infections/diagnosis , Coronavirus Infections/prevention & control , Betacoronavirus , Laboratories/standards , Infection Control/standards , Safety Management/statistics & numerical data , Genomics/trends , Pandemics/prevention & control , Public Health Surveillance/methodsABSTRACT
La prevención ha pasado de ser un abordaje específico en el ámbito de algunas enfermedades a ser un valor central en los discursos y la organización de los sistemas de salud. No obstante, la prevención no es un valor absoluto sin externalidades negativas, problemas de gestión del conocimiento o utilización del poder, sino que su popularización y expansión ha supuesto el incremento de los inconvenientes derivados de la gestión inadecuada del riesgo, la utilización a nivel poblacional de valores éticos desarrollados en el ámbito de la ética clínica individual y la medicalización de la vida diaria, más acusada con los nuevos paradigmas surgidos de la medicina post-genómica. En este artículo se tratan de abordar los riesgos clave de la deriva preventiva de los sistemas de salud y destacar los aspectos que deberían caracterizar las actividades preventivas de las próximas décadas
Prevention has gone from being a specific approach in the field of some diseases to being a central value in discourses and the organization of health systems. However, prevention is not an absolute value without negative externalities, knowledge management problems or use of power, but its popularization and expansion have led to an increase in the drawbacks derived from inadequate risk management, population-level utilization of ethical values developed in the field of individual clinical ethics and the medicalization of daily life, more pronounced with the new paradigms arising from post-genomic medicine. This article tries to address the key risks of the preventive trend of health systems and highlight the aspects that should characterize the preventive activities of the coming decades
Subject(s)
Humans , Disease Prevention , Mental Disorders/prevention & control , Medicalization/trends , 17627 , Evaluation of Results of Preventive Actions , 55790 , 50207 , Genomics/trends , Suicide/prevention & control , Depression/prevention & controlABSTRACT
El artículo realiza una valoración en torno a la evolución de la medicina del futuro y su incidencia en la protección de los derechos fundamentales. El autor centra su discurso en dos enfoques que, en la actualidad, parecen dominar el campo de la medicina: la medicina genómica y la medicina personalizada de precisión, entendiendo que existen diferencias entre medicina genómica y medicina personalizada de precisión que no permiten identificarlas. Una amplia exposición es dedicada al tema que el autor considera más relevante en la actualidad, esto es, el de la medicina personalizada de precisión, íntimamente ligada a los big data y a la inteligencia artificial
This paper deals with the evolution of the medicine of the future and its impact on the protection of fundamental rights. The author focuses the discourse on two approaches that currently seem to dominate the field of medicine: genomic medicine and personalized precision medicine, understanding that there are differences between genomic medicine and personalized precision medicine that do not allow them to be identified. An extensive exposition is dedicated to the subject that the author considers most relevant today, that is, precision personalized medicine, intimately linked to big data and artificial intelligence
Subject(s)
Humans , Precision Medicine/trends , Human Rights/trends , Genomics/trends , Big Data , Artificial Intelligence/trends , Biometric Identification/trends , Privacy/legislation & jurisprudence , Health Status Disparities , ForecastingABSTRACT
La medicina personalizada, medicina de precisión o medicina individualizada ha sido definida como una manera de abordar el tratamiento y la prevención de las enfermedades en base a la variabilidad genética, ambiental y al estilo de vida de cada persona. Clasifica a los individuos en subpoblaciones que difieren en la susceptibilidad a desarrollar una enfermedad determinada o en la respuesta a un tratamiento específico, con el fin de aplicar el seguimiento y tratamiento más adecuado a cada paciente. La implementación de los procesos asociados a la Medicina Personalizada implica que los profesionales de laboratorio se enfrenten a una tecnología muy avanzada y poco conocida y a la dificultad de interpretación de los hallazgos, especialmente la valoración de su significación clínica. En este artículo se revisa la situación actual de la Medicina Personalizada, la función del laboratorio dentro de la misma y los retos que se deben afrontar
Personalised medicine, precision medicine, or individualised medicine has been defined as the way of preventing and treating diseases based on the genetic, environmental, and lifestyle variability for each individual. It classifies subjects into sub-populations that have different susceptibilities to develop a specific disease or to respond to a particular treatment. Its aim is to follow-up and treat each patient in the more suited to the patient. The establishment of the processes related to personalised medicine requires that specialists in Laboratory Medicine cope with cutting-edge, and little-known, technology with an interpretation that is highly complex from a clinical point of view. This review summarises the current situation of personalised medicine, the role of laboratory medicine in its implementation, and the challenges that need to be faced
Subject(s)
Humans , Precision Medicine/trends , Medical Laboratory Science/trends , Patient-Specific Modeling/trends , Genomics/trends , Pharmacogenetics/trends , Research ReportABSTRACT
En esta revisión se analiza el avance que han experimentado los conocimientos biológicos como consecuencia del descubrimiento y manipulación de los genes, las interacciones de la genética y la medicina, y las perspectivas de la edición genómica
This review analyses the advances of biological knowledge derived from the discovery and handling of genes, the connections between genetics and medicine and the perspectives of genomic editing
Subject(s)
Humans , Animals , History, 18th Century , History, 19th Century , Genes , Genomics/methods , Genomics/trends , Eugenics/history , Eugenics/methods , Gene Expression , Gene Editing/trends , Sex Chromosomes , Drosophila melanogaster , Polymerase Chain ReactionSubject(s)
Humans , Diagnostic Techniques and Procedures/trends , Proteome , Genomics/methods , Genomics/trends , Metabolome , TranscriptomeABSTRACT
No disponible
Subject(s)
Humans , Precision Medicine/trends , Primary Health Care/trends , Genomics/trends , Individual Diseases/trends , Patient-Specific Modeling/trendsABSTRACT
Los avances de la genética en las últimas décadas han sido espectaculares. Sus implicaciones en la medicina fueron tan relevantes que el médico de familia no puede permanecer ajeno a ellas. Sin embargo, curiosamente, nuestro programa formativo de la especialidad apenas tiene contenidos relacionados con esta disciplina. Por ello, varias publicaciones han alertado de la necesidad de corregir este déficit y determinar los conocimientos, competencias y habilidades en genética que deberían adquirir los médicos de familia. Se considera que, además de unos conceptos generales, debemos tener formación relativa a las pruebas genéticas, asesoramiento genético, aspectos relacionados con los cánceres hereditarios y conocer los límites éticos y legales de la información genética. Por otra parte, también es necesario establecer unas pautas de colaboración con los servicios de genética (AU)
There have been spectacular advances in genetics in the last decades. Their implications in medicine have been so relevant that the family doctor cannot ignore them. However, interestingly, our specialty training program has hardly any contents related to this discipline. For this reason, several publications have warned of the need to correct this deficit and to determine the knowledge, skills and abilities in genetics that should be acquired by family physicians. It is considered that, in addition to some general concepts, we must have training related to genetic testing, genetic counselling, aspects related to hereditary cancers, and to be aware of the ethical and legal limits of genetic information. It is also necessary to establish guidelines for collaboration with the genetic services (AU)
Subject(s)
Humans , Family Practice/trends , Precision Medicine/trends , Genetics, Medical/trends , Primary Health Care/trends , Genomics/trends , Education, Medical/trends , Genetic Testing , Genetic CounselingABSTRACT
No disponible
Subject(s)
Humans , Genomics/trends , Breast Neoplasms/genetics , Transcriptome/genetics , Genes, erbB-2/genetics , Genes, erbB/genetics , Proteomics/trendsABSTRACT
OBJECTIVES: With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pretreated patients with metastatic cancer. METHODS: We analyzed metastatic cancer patients from a single institution whose cancers had progressed after all available standard-of-care therapies and whose tumors underwent next-generation sequencing analysis. We determined the percentage of patients who received any therapy directed by the test, and its efficacy. RESULTS: From July 2013 to December 2015, 185 consecutive patients were tested using a commercially available next-generation sequencing-based test, and 157 patients were eligible. Sixty-six patients (42.0%) were female, and 91 (58.0%) were male. The mean age at diagnosis was 52.2 years, and the mean number of pre-test lines of systemic treatment was 2.7. One hundred and seventy-seven patients (95.6%) had at least one identified gene alteration. Twenty-four patients (15.2%) underwent systemic treatment directed by the test result. Of these, one patient had a complete response, four (16.7%) had partial responses, two (8.3%) had stable disease, and 17 (70.8%) had disease progression as the best result. The median progression-free survival time with matched therapy was 1.6 months, and the median overall survival was 10 months. CONCLUSION: We identified a high prevalence of gene alterations using an next-generation sequencing test. Although some benefit was associated with the matched therapy, most of the patients had disease progression as the best response, indicating the limited biological potential and unclear clinical relevance of this practice.